MedTrace Logo

A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)

NCT02345213 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2019-01-08

No results posted yet for this study

Summary

The purpose of this study is to confirm the efficacy of Aricept in patients with dementia with Lewy bodies (DLB).

Conditions

  • Dementia, Lewy Body
  • Lewy Body Disease

Interventions

DRUG

E2020

E2020 tablets will be orally administered once daily after breakfast

DRUG

Placebo

Matching placebo tablets will be orally administered once daily after breakfast

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Megumi Ohdake · Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-01
Primary Completion
2017-05-15
Completion
2018-03-26

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02345213 on ClinicalTrials.gov